BioCentury

8:00 AM GMT, Jan 31, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Selling mouse futures

The two most popular mouse platforms to discover human antibodies, Abgenix Inc.'s XenoMouse and Medarex Inc.'s HuMAb Mouse, have been licensed only once since Abgenix was acquired by Amgen Inc. in 2005 and Medarex was acquired by Bristol-Myers Squibb Co. in 2009. Ablexis LLC hopes to fill the gap in the marketplace with its next-generation AlivaMab Mouse and a licensing model that provides a quick ROI for its investors.

Ablexis has released few details about its platform. However, CEO Larry Green told

Read the full 814 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.